725 related articles for article (PubMed ID: 9256137)
21. Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer.
Smith MR; Fallon MA; Goode MJ
Urology; 2003 Jan; 61(1):127-31. PubMed ID: 12559282
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of maximal androgen blockade versus castration alone in the treatment of advanced prostate cancer: a retrospective clinical experience from a Chinese medical centre.
Chen XQ; Huang Y; Li X; Zhang P; Huang R; Xia J; Chen N; Wei Q; Zhu YC; Yang YR; Zeng H
Asian J Androl; 2010 Sep; 12(5):718-27. PubMed ID: 20694018
[TBL] [Abstract][Full Text] [Related]
23. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
Sciarra A; Di Silverio F
Urology; 2004 Mar; 63(3):523-7. PubMed ID: 15028450
[TBL] [Abstract][Full Text] [Related]
24. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
[TBL] [Abstract][Full Text] [Related]
25. Rapid disease progression after the administration of bicalutamide in patients with metastatic prostate cancer.
Laufer M; Sinibaldi VJ; Carducci MA; Eisenberger MA
Urology; 1999 Oct; 54(4):745. PubMed ID: 10754148
[TBL] [Abstract][Full Text] [Related]
26. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
[TBL] [Abstract][Full Text] [Related]
27. Reversibility of androgen deprivation therapy in patients with prostate cancer.
Fridmans A; Chertin B; Koulikov D; Lindenberg T; Gelber H; Leiter C; Farkas A; Spitz IM
J Urol; 2005 Mar; 173(3):784-9. PubMed ID: 15711270
[TBL] [Abstract][Full Text] [Related]
28. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy.
Kojima S; Suzuki H; Akakura K; Shimbo M; Ichikawa T; Ito H
J Urol; 2004 Feb; 171(2 Pt 1):679-83. PubMed ID: 14713785
[TBL] [Abstract][Full Text] [Related]
29. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
Kunath F; Grobe HR; Rücker G; Motschall E; Antes G; Dahm P; Wullich B; Meerpohl JJ
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009266. PubMed ID: 24979481
[TBL] [Abstract][Full Text] [Related]
30. Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma.
Chodak G; Sharifi R; Kasimis B; Block NL; Macramalla E; Kennealey GT
Urology; 1995 Dec; 46(6):849-55. PubMed ID: 7502428
[TBL] [Abstract][Full Text] [Related]
31. Bicalutamide dosages used in the treatment of prostate cancer.
Kolvenbag GJ; Nash A
Prostate; 1999 Apr; 39(1):47-53. PubMed ID: 10221266
[TBL] [Abstract][Full Text] [Related]
32. [Antiandrogen in prostate cancer].
Maeda O; Usami M
Nihon Rinsho; 2002 Dec; 60 Suppl 11():188-92. PubMed ID: 12599569
[No Abstract] [Full Text] [Related]
33. A Randomized Control Trial Comparing the Efficacy of Antiandrogen Monotherapy: Flutamide vs. Bicalutamide.
Nakai Y; Tanaka N; Anai S; Miyake M; Tatsumi Y; Fujimoto K
Horm Cancer; 2015 Aug; 6(4):161-7. PubMed ID: 26024831
[TBL] [Abstract][Full Text] [Related]
34. Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide?
Ramsey S; Veenstra D; Clarke L; Gandhi S; Hirsch M; Penson D
Urology; 2005 Oct; 66(4):835-9. PubMed ID: 16230148
[TBL] [Abstract][Full Text] [Related]
35. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
Raina R; Pahalajani G; Agarwal A; Zippe C
Asian J Androl; 2007 Mar; 9(2):253-8. PubMed ID: 17334592
[TBL] [Abstract][Full Text] [Related]
36. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).
Sartor AO; Tangen CM; Hussain MH; Eisenberger MA; Parab M; Fontana JA; Chapman RA; Mills GM; Raghavan D; Crawford ED;
Cancer; 2008 Jun; 112(11):2393-400. PubMed ID: 18383517
[TBL] [Abstract][Full Text] [Related]
37. Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen.
Narimoto K; Mizokami A; Izumi K; Mihara S; Sawada K; Sugata T; Shimamura M; Miyazaki K; Nishino A; Namiki M
Int J Urol; 2010 Apr; 17(4):337-45. PubMed ID: 20202011
[TBL] [Abstract][Full Text] [Related]
38. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study.
Boccardo F; Rubagotti A; Barichello M; Battaglia M; Carmignani G; Comeri G; Conti G; Cruciani G; Dammino S; Delliponti U; Ditonno P; Ferraris V; Lilliu S; Montefiore F; Portoghese F; Spano G
J Clin Oncol; 1999 Jul; 17(7):2027-38. PubMed ID: 10561254
[TBL] [Abstract][Full Text] [Related]
39. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival.
Akaza H; Hinotsu S; Usami M; Arai Y; Kanetake H; Naito S; Hirao Y;
Cancer; 2009 Aug; 115(15):3437-45. PubMed ID: 19536889
[TBL] [Abstract][Full Text] [Related]
40. Bicalutamide versus flutamide in combination therapy.
Labrie F; Candas B
Urology; 1999 Mar; 53(3):662-3. PubMed ID: 10096411
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]